Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sutro BiopharmaSTRO -4.16%45 5-Year Dividend Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates STRO with a GF Score™ of 45/100 and a GF Value™ of $5.50 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 56 Biotechnology companies, Sutro Biopharma ranks worse than 1785712.5% on this metric.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sutro Biopharma 5-Year Dividend Growth Rate Related Terms
STRO vs AVIR, IPSC, CCCC: 5-Year Dividend Growth Rate Comparison
For the Biotechnology subindustry, Sutro Biopharma's 5-Year Dividend Growth Rate, along with its competitors' market caps and 5-Year Dividend Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sutro Biopharma 5-Year Dividend Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sutro Biopharma's 5-Year Dividend Growth Rate distribution charts can be found below:
* The bar in red indicates where Sutro Biopharma's 5-Year Dividend Growth Rate falls into.
This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 5-Year Dividend Growth Rate of 0.00% mean?
Sutro Biopharma (STRO) has a 5-Year Dividend Growth Rate of 0.00% as of Jun. 2026. 5-Year Dividend Growth Rate is the company's five-year average growth of dividend payout. View historical data on Sutro Biopharma and its competitors. According to the industry distribution chart, Sutro Biopharma ranks #999999 out of 56 companies in the Biotechnology industry.
Is Sutro Biopharma's 5-Year Dividend Growth Rate too high?
Sutro Biopharma's current 5-Year Dividend Growth Rate is 0.00%. Based on the distribution chart, Sutro Biopharma ranks #999999 out of 56 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sutro Biopharma has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sutro Biopharma's 5-Year Dividend Growth Rate compare to AVIR and IPSC?
According to the Biotechnology industry distribution chart, Sutro Biopharma ranks #999999 out of 56 companies for 5-Year Dividend Growth Rate. This places Sutro Biopharma in the lower half of its industry. The industry median 5-Year Dividend Growth Rate is 9.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Dividend Growth Rate for a Biotechnology company?
The median 5-Year Dividend Growth Rate among Biotechnology companies is 9.70, based on 56 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Dividend Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Dividend Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Dividend Growth Rate mean?
A high 5-Year Dividend Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year Dividend Growth Rate is the company's five-year average growth of dividend payout. View historical data on Sutro Biopharma and its competitors. For the Biotechnology industry, the median 5-Year Dividend Growth Rate is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sutro Biopharma's current 5-Year Dividend Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sutro Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Sutro Biopharma (STRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.50, compared to a current price of $20.46 — trading 272% above its estimated fair value. The current 5-Year Dividend Growth Rate is 0.00%. Sutro Biopharma's overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Dividend Growth Rate calculated?
5-Year Dividend Growth Rate is calculated from a company's financial statements. For Sutro Biopharma (STRO), the current 5-Year Dividend Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sutro Biopharma (STRO) Overvalued in 2026?
Based on GuruFocus' analysis, Sutro Biopharma stock appears to be overvalued.
The current stock price of $20.46 is trading 272% above its estimated GF Value™ of $5.50.
GuruFocus considers Sutro Biopharma to be Significantly Overvalued.
Key valuation signals for STRO:
5-Year Dividend Growth Rate: 0.00%
GF Value™: $5.50 vs. price of $20.46 (272% above fair value)
No single metric tells the full story. See the STRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
45GF Score
Get the complete analysis for STRO
5-Year Dividend Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STRO has been successfully added to your 
